Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuro-Oncology and Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DCX drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DCX Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native post-translational phosphorylation. |
View DCX Products |
| Gene Delivery | DCX Promise-ORF / Lentivirus Full-length ORF for stable cell lines to analyze microtubule polymerization and cell migration. |
View DCX Products |
| Benchmark Ab | Anti-DCX Recombinant Antibody Recombinant positive control for immunohistochemistry (IHC) and Western Blot validation. |
View DCX Products |
| Validator | DCX siRNA Set For target knockdown verification in neural stem cells or glioblastoma models. |
View DCX Products |
| Related Target A | TUBB3 Class III beta-tubulin; major partner in microtubule stabilization and neuronal migration pathways. |
View TUBB3 Products |
| Related Target B | NES Nestin; neural stem cell marker co-expressed during neurogenesis and brain tumor progression. |
View NES Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Microtubule binding and polymerization evaluation | Sequence-verified, high-purity recombinant DCX protein preserving native structural domains. |
| Phosphorylation-dependent activity screening | HEK293 expression system ensuring human-like post-translational modifications (PTMs). |
| Lack of Controls | Recombinant Benchmark Antibodies included for highly reproducible assay baselines. |
| False Positives in Knockdown Studies | Sequence-specific siRNA sets included for robust target validation. |
Live DCX R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DCX therapeutics is intensifying, with major players shifting focus from traditional biomarkers to active therapeutic modulation in neuro-oncology and regenerative medicine. As first-generation therapies reach the clinic, the next wave of R&D is targeting DCX-mediated microtubule dynamics to halt glioblastoma invasion and promote neural repair.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Academic Medical Centers, Biotech Startups | Glioblastoma, Lissencephaly | Microtubule co-sedimentation assays (Need high-purity recombinant DCX) |
| Gene Therapy / RNA | Neuro-regeneration Biopharma | Spinal Cord Injury, Neurodegenerative diseases | In vitro target knockdown validation (Need sequence-verified DCX siRNA) |
| Cell Therapy Validation | Stem Cell Therapeutics Companies | Neuronal Differentiation QC | Lineage tracking & expression QC (Need highly specific anti-DCX recombinant antibodies) |